The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals
Abstract
The pharmaceutical co-crystal approach has been introduced recently to address poor physicochemical properties of new chemical entities. In this study we prepared and investigated ten co-crystals of AMG 517. Based on thermal analysis, 1 H NMR and p K a values we have prepared co-crystals rather than solvates or salts. We explored co-crystal physicochemical properties such as particle size, solubility, stability, hygroscopicity, and thermal properties as well as hydrogen bonding networks. We found that all co-crystals, for which we obtained single crystal structure, had the same two hydrogen bonds between the compound and the co-crystal former. In addition, we found good correlation between the melting point of the co-crystal former and the co-crystal but less correlation between the melting point and solubility of the co-crystals. In conclusion, within this series of co-crystals some design is possible by considering features of the compound and the co-crystal former.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Molecular mechanisms of nociception
Julius, D., & Basbaum, A. I. (2001) · Nature · doi:10.1038/35093019 · Cited by 2,685
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
Dressman, J. B., Amidon, G. L., Reppas, C., & Shah, V. P. (1998) · Pharmaceutical Research · doi:10.1023/a:1011984216775 · Cited by 1,097
Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).
Prentis, R., Lis, Y., & Walker, Sr. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03318.x · Cited by 471
Gavva, N. R., Bannon, A. W., Hovland, D. N., Lehto, S. G., Klionsky, L., Surapaneni, S., Immke, D. C., Henley, C., Arik, L., Bak, A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125674 · Cited by 180
Self-citation
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Solubility Advantage of Pharmaceutical Cocrystals
Good, D. J., & Rodríguez-Hornedo, N. (2009) · Crystal Growth & Design · doi:10.1021/cg801039j · Cited by 841
Pharmaceutical cocrystals: An overview
Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., & Trappitt, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.037 · Cited by 665
Pharmaceutical cocrystals and poorly soluble drugs
Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.043 · Cited by 614
Morrison, H. G., Sun, C. C., & Neervannan, S. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.039 · Cited by 552
Berry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
An overview of recent studies on the analysis of pharmaceutical polymorphs
Chieng, N., Rades, T., & Aaltonen, J. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.12.020 · Cited by 285
Metadata
- Authors
- Stanton, M. K., & Bak, A.
- Venue
- Crystal Growth & Design
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-09-04
- Volume
- 8
- Issue
- 10
- Pages
- 3856-3862
- ISSN
- 1528-7483 (ISSN-L)
- 1528-7505
- OpenAlex
- W2063548340
- Cited by
- 236
- References
- 6
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.